Ken Fisher's REGN Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 4,990 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $3.85 M, representing 0.00% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in REGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2019, adding 4,264 shares. Largest reduction occurred in Q1 2025, reducing 1,537 shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +353 | Add 7.61% | 4,990 | $772.06 |
| Q3 2025 | +284 | Add 6.52% | 4,637 | $562.41 |
| Q1 2025 | -1,537 | Reduce 26.10% | 4,353 | $634.37 |
| Q4 2024 | +833 | Add 16.47% | 5,890 | $712.51 |
| Q3 2024 | -608 | Reduce 10.73% | 5,057 | $1051.32 |
| Q2 2024 | -149 | Reduce 2.56% | 5,665 | $1051.07 |
| Q1 2024 | +192 | Add 3.42% | 5,814 | $962.54 |
| Q4 2023 | +472 | Add 9.17% | 5,622 | $878.35 |
| Q3 2023 | -218 | Reduce 4.06% | 5,150 | $823.10 |
| Q2 2023 | +1,001 | Add 22.92% | 5,368 | $718.54 |
| Q1 2023 | -239 | Reduce 5.19% | 4,367 | $821.67 |
| Q4 2022 | -13 | Reduce 0.28% | 4,606 | $721.67 |
| Q3 2022 | +50 | Add 1.09% | 4,619 | $688.89 |
| Q2 2022 | +3 | Add 0.07% | 4,569 | $591.16 |
| Q1 2022 | -650 | Reduce 12.46% | 4,566 | $698.42 |
| Q4 2021 | +142 | Add 2.80% | 5,216 | $631.52 |
| Q3 2021 | -85 | Reduce 1.65% | 5,074 | $605.24 |
| Q2 2021 | +44 | Add 0.86% | 5,159 | $558.64 |
| Q1 2021 | -112 | Reduce 2.14% | 5,115 | $473.12 |
| Q4 2020 | -44 | Reduce 0.83% | 5,227 | $483.07 |
| Q3 2020 | +130 | Add 2.53% | 5,271 | $559.86 |
| Q2 2020 | -2 | Reduce 0.04% | 5,141 | $623.61 |
| Q1 2020 | -145 | Reduce 2.74% | 5,143 | $488.24 |
| Q4 2019 | -159 | Reduce 2.92% | 5,288 | $375.57 |
| Q3 2019 | +18 | Add 0.33% | 5,447 | $277.40 |
| Q2 2019 | -99 | Reduce 1.79% | 5,429 | $312.95 |
| Q1 2019 | +4,264 | Add 337.34% | 5,528 | $410.64 |
| Q4 2018 | -14 | Reduce 1.10% | 1,264 | $373.42 |
| Q3 2018 | -302 | Reduce 19.11% | 1,278 | $403.76 |
| Q2 2018 | +250 | Add 18.80% | 1,580 | $344.94 |
| Q1 2018 | -135 | Reduce 9.22% | 1,330 | $344.36 |
| Q4 2017 | -109 | Reduce 6.93% | 1,465 | $376.11 |
| Q3 2017 | +163 | Add 11.55% | 1,574 | $447.27 |
| Q2 2017 | +605 | Add 75.06% | 1,411 | $491.14 |
| Q1 2017 | +91 | Add 12.73% | 806 | $387.10 |
| Q4 2016 | +95 | Add 15.32% | 715 | $366.43 |
| Q3 2016 | +7 | Add 1.14% | 620 | $401.61 |
| Q1 2016 | -2 | Reduce 0.33% | 613 | $406.20 |
| Q4 2015 | +111 | Add 22.02% | 615 | $543.09 |
| Q3 2015 | -61 | Reduce 10.80% | 504 | $464.29 |
| Q2 2015 | +31 | Add 5.81% | 565 | $509.73 |
| Q1 2015 | +10 | Add 1.91% | 534 | $451.31 |
| Q4 2014 | -59 | Reduce 10.12% | 524 | $410.31 |
| Q3 2014 | +583 | New Buy | 583 | $360.21 |
Ken Fisher's Regeneron Pharmaceuticals Investment FAQs
Ken Fisher first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q3 2014, acquiring 583 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Regeneron Pharmaceuticals, Inc. (REGN) for 46 quarters since Q3 2014.
Ken Fisher's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q1 2019, adding 5,528 shares worth $2.27 M.
According to the latest 13F filing for Q4 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 4,990 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $3.85 M.
As of the Q4 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 5,890 shares, as reported at the end of Q4 2024.